Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Deme J. Karikios"'
Autor:
Anupriya Agarwal, Ann Livingstone, Deme J. Karikios, Martin R. Stockler, Philip J. Beale, Rachael L. Morton
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Optimising the care of individuals with cancer without imposing significant financial burden related to their anticancer treatment is becoming increasingly difficult. The American Society of Clinical Oncology (ASCO) has recommende
Externí odkaz:
https://doaj.org/article/80abb7d222664d61bea0a974e17e4228
Autor:
Ray Moynihan, Peter Fox, Lisa A Bero, Barbara Mintzes, Eliza J McEwin, Adrian M J Pokorny, Deme J Karikios
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Objectives To understand how and why Australian cancer physicians interact with the pharmaceutical industry.Design Qualitative study using semistructured interviews, performed by a medical oncologist. Thematic analysis using a combination of deductiv
Externí odkaz:
https://doaj.org/article/4507fbea3d454da98871890e0e62cab4
Publikováno v:
PLoS ONE, Vol 17, Iss 10, p e0273620 (2022)
BackgroundA diagnosis of cancer is associated with significant physical, psychological and financial burden. Including costs of cancer is an important component of shared decision making. Doctors bear a responsibility towards educating patients about
Externí odkaz:
https://doaj.org/article/df72767972ec461e82b6ef725cf65168
Autor:
Louisa G. Gordon, Doreen Nabukalu, Raymond J. Chan, David E. Goldsbury, Kim Hobbs, Lee Hunt, Deme J. Karikios, Gillian Mackay, Laura Muir, Lillian Leigh, Carla Thamm, Daniel Lindsay, Kate Whittaker, Megan Varlow, Jordana McLoone, on behalf of the COSA Financial Toxicity Working Group
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 19:126-135
To understand the opinions and current practices of health professionals on the topic of addressing cancer-related financial toxicity among patients.A cross-sectional online survey was distributed through Australian clinical oncology professional org
Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods
Autor:
Preston J. Ngo, Sonya Cressman, Silvia Behar-Harpaz, Deme J. Karikios, Karen Canfell, Marianne F. Weber
Publikováno v:
Lung Cancer. 166:122-131
Lung cancer screening with low-dose computed tomography (LDCT) in high-risk populations has been shown in randomised controlled trials to lead to early diagnosis and reduced lung cancer mortality. However, investment into screening will largely depen
Autor:
Adrian M J Pokorny, Lisa A Bero, Peter Fox, Deme J Karikios, Eliza J McEwin, Ray Moynihan, Barbara Mintzes
Publikováno v:
BMJ Open. 13:e065719
ObjectivesTo understand how and why Australian cancer physicians interact with the pharmaceutical industry.DesignQualitative study using semistructured interviews, performed by a medical oncologist. Thematic analysis using a combination of deductive
Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions
Autor:
Adrian M.J. Pokorny, Ray Moynihan, Peter Fox, Deme J. Karikios, Lisa A. Bero, Barbara J. Mintzes
Publikováno v:
JCO oncology practice. 18(7)
PURPOSE: Interactions between cancer physicians and the pharmaceutical industry may create conflicts of interest that can adversely affect patient care. We aimed to survey cancer physicians regarding their attitudes toward and interactions with indus
Autor:
Deme J, Karikios, Lesley, Chim, Andrew, Martin, Adnan, Nagrial, Kirsten, Howard, Glenn, Salkeld, Martin R, Stockler
Publikováno v:
Internal medicine journal. 47(4)
Australians access anticancer drugs predominantly through the Pharmaceutical Benefits Scheme (PBS).To determine why the Pharmaceutical Benefits Advisory Committee (PBAC) rejects submissions to list anticancer drugs on the PBS.We reviewed publicly ava